Sientra, Inc. Stock Price, News & Analysis

Sientra, Inc. (NASDAQ: SIEN) will participate in the William Blair 42nd Annual Growth Stock Conference from June 6-9, 2022. The company's management will deliver a live presentation on June 7, 2022, at 4:00 PM CDT / 2:00 PM PDT. An on-demand webcast of the presentation will be available on Sientra's website for 90 days afterward. Sientra specializes in medical aesthetics, offering a diverse range of products, including advanced breast implants and innovative fat grafting systems. For more details, visit www.sientra.com.

Sientra, Inc. (NASDAQ: SIEN) will participate in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022. This virtual event is for prospective and existing Craig-Hallum clients. Interested parties can contact their representatives for one-on-one meetings with Sientra management.

Based in Santa Barbara, Sientra is a leader in medical aesthetics, focusing on innovative products for plastic surgery. Their offerings include FDA-approved breast implants and advanced surgical technologies, supported by strong clinical results.

Sientra, a medical aesthetics company, reported first-quarter 2022 net sales of $21.4 million, up 17% year-over-year, driven by 50% growth in reconstruction. Gross margins improved to 60% due to better operational efficiencies. The company expanded its market share in both augmentation and reconstruction, adding over 200 new accounts. Sientra aims for 2022 net sales of $93-$97 million, reflecting 15%-20% growth from 2021. However, operating expenses rose to $28.9 million, up from $21.9 million.

Sientra, Inc. (NASDAQ: SIEN) has announced its financial results for Q1 2022 will be released on May 12, 2022, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day. Investors can access the call by dialing +1 (877) 270-2148 for domestic calls or +1 (412) 902-6510 for international calls, using conference ID 10166923. A live webcast will be available on their Investor Relations website and will be archived afterward.

Sientra (NASDAQ: SIEN) announced that CEO Ron Menezes will present at the 2022 Virtual Growth Conference hosted by Maxim Group LLC from March 28-30, 2022. The presentation will occur during the "Aesthetics Device Industry Panel" on March 28 at 1:00 PM EDT. Interested attendees can register and view the panel on Maxim's M-Vest platform. Sientra is focused on advancing plastic surgery through innovative products, including FDA-approved breast implants and the Allox2® breast tissue expander.

Sientra, Inc. (NASDAQ: SIEN) has received approval from Health Canada to market its High-Strength Cohesive (HSC and HSC+) silicone gel breast implants in Canada, marking a significant milestone in the company’s international expansion efforts. Sientra becomes the third manufacturer in Canada, introducing advanced technologies and a strong ten-year safety data backing. The implants will be marketed in partnership with Kai Aesthetic, ensuring high safety and product standards. The approval is expected to benefit Canadian plastic surgeons and their patients.

Sientra, Inc. (NASDAQ: SIEN) reported its Q4 and full-year 2021 financial results, showcasing a 26.6% increase in Q4 net sales to $22.6 million and a 47% growth for the year to $80.7 million. The company expanded its market share in Augmentation and Reconstruction to approximately 11% and 14% respectively. Despite a loss from continuing operations of $62.5 million for the year, the cash position remains strong at $51.8 million. For 2022, Sientra anticipates net sales of $93 million to $97 million, a projected growth of 15% to 20%.

Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, will release its financial results for Q4 and the full year of 2021 on March 23, 2022, after market close. A conference call is scheduled for the same day at 4:30 PM ET, where they will discuss the results. Investors can access the call via dial-in numbers or a live webcast on the investor relations section of their website. Sientra focuses on providing innovative products for plastic surgery, including FDA-approved breast implants and advanced surgical tools.

Sientra, Inc. (NASDAQ: SIEN) announced preliminary financial results for Q4 and the full year 2021, projecting annual revenue of $80-$81 million, marking a significant 46%-47% growth year-over-year. The fourth-quarter revenue is anticipated to be between $22-$23 million, representing a 23%-29% increase from the same quarter in 2020. This performance is attributed to strong market demand for Sientra's Breast Products and effective commercial strategies. The company also highlighted the benefits of acquiring Auragen Aesthetics' fat grafting technology, enhancing its position in the plastic surgery market.